May 03 2023
News from the National Academy of Sciences
Newly elected member Anthony A. Kossiakoff; Professor, Department of Biochemistry and Molecular Biology, The University of Chicago
Three University of Chicago faculty members elected to the National Academy of Sciences in 2023
Mar 01 2021
The Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco (UCSF), the University of Chicago, and the University of Toronto have expanded a previous research collaboration with Bristol Myers Squibb, aimed to create and develop high-performance recombinant antibodies against diverse targets in human cells.
The RAN was founded in 2012 by …
Jul 06 2020
Patent-of-the-week-improving-the-performance-of-antibody-fragments
Antibody fragments, including Fabs, which bind to immune response-triggering substances, or antigens, have demonstrated utility in various research and diagnostic applications. However, their structure limits their use, so researchers have engineered a protein that can be tethered to Fabs to expand their functionality.
The inventors, including Anthony Kossiakoff, a professor of biochemistry and molecular …
Jan 02 2020
The Christian B. Anfinsen Award- Sponsored by The Protein Society, recognizes technological achievement or significant methodological advances in the field of protein science.
The recipient of this award in 2019 is Professor Anthony Kossiakoff (University of Chicago). Professor Kossiakoff’s achievements have had broad and sustained impact through the development of innovative technologies and major discoveries …
Dec 11 2019
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced a partnership with the Recombinant Antibody Network (RAN), a consortium of three expert centers at the University of Chicago, University of Toronto, and UC San Francisco (UCSF) with a common goal to generate recombinant antibodies at a proteome-wide scale.
Jan 29 2018
Advanced robotic system designed to screen thousands of recombinant antibodies without human intervention.